Richard D. Hall

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares et al. · Annals of Oncology · 2023 · 55 citations · Full text

Medicine, Oncology, Pharmacology +12

A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials

Lawrence S. Gazda, James E. Collins, Archie Lovatt et al. · Xenotransplantation · 2016 · 54 citations · Full text

Life Sciences, Animal Sciences, Microbiology +14